News Related to OX2R Agonist

Related coverage linked through entity extraction aliases.

FDA Grants Priority Review to Takeda's Oveporexton for Narcolepsy Type 1

May 03, 2025

The FDA accepted Takeda's NDA for oveporexton (TAK-861), an oral orexin receptor 2 agonist for narcolepsy type 1, and granted Priority Review with a PDUFA goal date in Q3 2026. The drug could become the first approved orexin agonist.

Drug Hunter's Most Popular Content of 2025 Highlights Industry Trends

Dec 30, 2025

Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.